1. Convalescent plasma as a treatment modality for coronavirus disease 2019 in Sudan
- Author
-
Asaad Tageldein Idris Abdelhalim, Susan Ali Zroog, Mozan Osman Hassan, Roaa Idris, Hala Rufai, Hana Elsir Abd Elbasit, Abduelbagi D.A. Altayb, Amna Khairy, Asma Ahmed Osman, Mushal Allam, Maria M.M. Satti, Ashraf Musa, Musab Elnegoumi, Abdelhakam H. Ali, and Hanan Elsamani Hassan
- Subjects
Male ,medicine.medical_specialty ,Convalescent plasma ,Coronavirus disease 2019 (COVID-19) ,Health authority ,Context (language use) ,Blood Component Transfusion ,030204 cardiovascular system & hematology ,Article ,Sudan ,03 medical and health sciences ,0302 clinical medicine ,Protocol ,Medicine ,Humans ,Intensive care medicine ,COVID-19 Serotherapy ,business.industry ,Donor selection ,SARS-CoV-2 ,Immunization, Passive ,COVID-19 ,Hematology ,Clinical trial ,Treatment ,Treatment intervention ,Treatment modality ,Female ,business ,030215 immunology - Abstract
Coronavirus disease 2019 (COVID-19) is a disease spreading rapidly in Sudan, the rest of the African continent and the world with no known definitive treatment or vaccines. However, among many treatment interventions being tested globally, beneficial effects and clinical improvements have been reported when convalescent plasma is used for treating COVID-19 patients. We prepared a guiding protocol for treating early to moderate COVID-19 patients with plasma transfusion from convalescent COVID-19 patients. This protocol was deduced based on previously published reports and studies that evaluated and tested convalescent plasma as a prospective therapy for COVID-19 patients. The protocol covers instructions on patient and donor selection criteria, plasma harvesting, plasma product specifications, dosage and precautions for convalescent plasma collection and transfusion process. Altogether, we prepared a treatment protocol that is tailored to the context of Sudan to be adopted by Sudan's health authority. Moreover, it will also provide reference for researchers to design open label clinical trials for convalescent plasma transfusion.
- Published
- 2020